# Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

> **NCT02081014** · PHASE2 · COMPLETED · sponsor: **Xeris Pharmaceuticals** · enrollment: 13 (actual)

## Conditions studied

- Hypoglycemia

## Interventions

- **DRUG:** G-Pen Mini™ (glucagon injection)

## Key facts

- **NCT ID:** NCT02081014
- **Lead sponsor:** Xeris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081014, "Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02081014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*